Another disappointing result, but how good is it?

Affiliations

Editorial

Yasushi Goto. J Thorac Dis. 2017 Jun.

. 2017 Jun;9(6):1426-1428.

doi: 10.21037/jtd.2017.05.40.

¹ Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.

No abstract available

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

Is the door open to further investigation with antiangiogenesis in SCLC?
Tiseo M, Boni L, Ardizzoni A. Tiseo M, et al. J Thorac Dis. 2018 Apr;10(Suppl 9):S1127-S1128. doi: 10.21037/jtd.2018.03.87. J Thorac Dis. 2018. PMID: 29850194 Free PMC article. No abstract available.

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.
Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, Brighenti M, Zanelli F, Defraia E, Chiari R, Dazzi C, Tibaldi C, Turolla GM, D'Alessandro V, Zilembo N, Trolese AR, Grossi F, Riccardi F, Ardizzoni A. Tiseo M, et al. J Clin Oncol. 2017 Apr 20;35(12):1281-1287. doi: 10.1200/JCO.2016.69.4844. Epub 2017 Jan 30. J Clin Oncol. 2017. PMID: 28135143 Clinical Trial.

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. 10.1016/S0092-8674(00)81683-9 - DOI - PubMed
1. Tiseo M, Boni L, Ambrosio F, et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. J Clin Oncol 2017;35:1281-7. 10.1200/JCO.2016.69.4844 - DOI - PubMed
1. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91. 10.1056/NEJMoa003034 - DOI - PubMed
1. Lara PN, Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-5. 10.1200/JCO.2008.20.1061 - DOI - PMC - PubMed
1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. 10.1056/NEJMoa061884 - DOI - PubMed